DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Bayer

Status: Not yet enrolling

Conditions: Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

Treatments: Drug: anti-VEGF medication

Study type: Observational

Funder types: Industry

Identifiers

NCT07308639

23110

Details and patient eligibility

About

The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are:

nAMD (neovascular age-related macular degeneration): a condition that affects the central part of the retina and can cause vision loss in older adults.

DME (diabetic macular edema): a swelling in the central part of the retina caused by diabetes, which can also lead to vision problems.

RVO (retinal vein occlusion): a blockage of the veins in the retina, which can cause sudden vision loss.

Researchers will look at data collected from 2009 to 2024 to see how often these diseases occur (incidence) and how many people have them at a given time (prevalence). They will use two large sets of health data from Germany, called FDZ and FDGP.

The main question is: How do the numbers of new and existing cases of nAMD, DME, and RVO compare between the two data sources (FDZ and FDGP) in Germany from 2009 to 2024? The study also wants to find out if factors like age, other health problems, and medications affect how common these eye diseases are.

Another goal is to see how many people with these eye diseases are treated with a type of medicine called anti-VEGF, which is used to slow down or stop vision loss.

In summary, this study will help us understand how these eye diseases affect people in Germany, how they are treated, and whether different groups of people are more likely to get them.

Enrollment: 50,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least one diagnosis of nAMD, DME and RVO in the timeframe 01 JAN 2009 until 31 DEC 2024
• nAMD patients aged ≥ 50 years
• DME patients aged ≥18 years
• RVO patients aged ≥18 years
• Participants living in Germany covered by statutory health insurance or private health insurance

Exclusion criteria

• none

Trial design

50,000 participants in 3 patient groups

nAMD cohort

Description:

participants diagnosed with nAMD

Treatment:

Drug: anti-VEGF medication

DME cohort

Description:

participants diagnosed with DME

Treatment:

Drug: anti-VEGF medication

RVO cohort

Description:

participants diagnosed with RVO

Treatment:

Drug: anti-VEGF medication